Landiolol for refractory tachyarrhythmias in the intensive care unit: case reports. (13th June 2022)

• Record Type: Journal Article
• Authors: Gangl, Clemens; Krychtiuk, Konstantin A; Schoenbauer, Robert; Speidl, Walter S
• Is Part Of: European heart journal supplements. Volume 24(2022)Supplement D
• Page Start: D43
• Page End: D49
• Publication Date: 2022-06-13
• Subjects: Case report -- Landiolol -- Sepsis -- Electrical storm; Cardiology -- Periodicals; Cardiology -- Europe -- Periodicals; 616.12005
• DOI: 10.1093/eurheartjsupp/suac026
• Languages: English
• ISSNs: 1520-765X

Abstract

Abstract: Tachyarrhythmias are common complications of critically ill patients treated on intensive care units. Landiolol is an ultra-short acting beta-blocker with a very high beta1-selectivity. Therefore, landiolol effectively reduces heart rate with only minimal negative effects on blood pressure and inotropy. This article describes two cases of successful treatment of supraventricular and ventricular tachycardias with landiolol in critically ill patients.